Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Sargent Investment Group LLC

Sargent Investment Group LLC lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.6% during the fourth quarter, HoldingsChannel reports. The fund owned 296,350 shares of the biotechnology company’s stock after selling 1,645 shares during the period. Exelixis comprises approximately 1.6% of Sargent Investment Group LLC’s investment portfolio, making the stock its 17th biggest holding. Sargent Investment Group LLC’s holdings in Exelixis were worth $7,109,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Russell Investments Group Ltd. grew its holdings in Exelixis by 2.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,513,591 shares of the biotechnology company’s stock valued at $36,314,000 after purchasing an additional 37,438 shares during the last quarter. Truist Financial Corp acquired a new stake in Exelixis in the fourth quarter valued at $218,000. State of New Jersey Common Pension Fund D grew its holdings in Exelixis by 8.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 184,279 shares of the biotechnology company’s stock valued at $4,421,000 after purchasing an additional 14,517 shares during the last quarter. Meritage Portfolio Management grew its holdings in Exelixis by 7.0% in the fourth quarter. Meritage Portfolio Management now owns 422,676 shares of the biotechnology company’s stock valued at $10,140,000 after purchasing an additional 27,815 shares during the last quarter. Finally, Alaska Permanent Fund Corp grew its holdings in Exelixis by 28.8% in the fourth quarter. Alaska Permanent Fund Corp now owns 52,622 shares of the biotechnology company’s stock valued at $1,262,000 after purchasing an additional 11,767 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ:EXEL traded up $0.17 during mid-day trading on Friday, hitting $23.70. 1,560,811 shares of the company traded hands, compared to its average volume of 1,843,234. The firm has a market cap of $6.99 billion, a P/E ratio of 37.03, a PEG ratio of 0.61 and a beta of 0.54. Exelixis, Inc. has a 52-week low of $18.08 and a 52-week high of $24.34. The firm’s 50 day simple moving average is $22.80 and its 200 day simple moving average is $22.19.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.25 by $0.02. The business had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Equities research analysts expect that Exelixis, Inc. will post 1.23 EPS for the current fiscal year.

Insider Activity at Exelixis

In other Exelixis news, Director David Edward Johnson acquired 190,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now directly owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Exelixis news, Director David Edward Johnson acquired 190,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now directly owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares in the company, valued at $8,255,375.70. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

EXEL has been the topic of several research reports. Stifel Nicolaus upped their target price on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Royal Bank of Canada lifted their price objective on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research report on Wednesday, April 10th. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.